logo-loader

Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer

Last updated: 06:19 10 Jun 2018 AEST, First published: 15:32 09 Jun 2018 AEST

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive Investors the biopharmaceutical company is developing a drug to make 'the new frontier' in cancer therapy safer therapy by developing its antibody to Phase II studies. 

Durrant says Humanigen's focus is on making chimeric antigen receipter T-cell (CAR-T) therapy safer and more effective, that minimizes the requirement to be in a hospital. Durrant says Humanigen's antibody called lenzilumab can block a molecule called GM-CSF, which is the key master switch that leads to brain inflammation, amoung other things. Durrant says Humanigen is excited to begin Phase II studies to test this, and are partnering with leading insitutions to begin clinical trials. Durrant says Humanigen is hoping to begin Phase II this year once the company completes fundraising. 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

7 hours, 14 minutes ago